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Abstract
Background Early diagnosis of tuberculous meningitis
(TBM) is still a challenge; the present study aimed to
establish a method of detecting the antigen early secreted
antigenic target 6 (ESAT-6) in cerebrospinal fluid (CSF)
by an indirect enzyme-linked immunosorbance assay
(ELISA) protocol and to study the value of detecting
ESAT-6 in CSF in the early diagnosis of TBM.
Methods An indirect ELISA protocol was used, employing
a monoclonal antibody (mAb) against ESAT-6, which was
used to demonstrate ESAT-6 in the CSF from TBM patients
and non-TBM controls. CSF was obtained from 100 patients:
confirmed TBM, clinically diagnosed TBM, disease con-
trols, and healthy controls (n = 10). Pure recombinant
ESAT-6 (standard product) was used in serial dilutions to
detect the absorbance and to establish a standard curve from
the data; the concentration was on the X axis vs. absorbance
on the Y axis, and the standard curve was used to interpolate
the concentration of ESAT-6 in samples.
Results The indirect ELISA method provided 88 % sensi-
tivity and 92 % specificity for the diagnosis of TBM using a
mAb to ESAT-6. The mean concentration of ESAT-6 in TBM
patients was significantly higher than that of the non-TBM
groups. There was also a significant difference in the mean
ESAT-6 expression between the confirmed TBM patients and
the clinically diagnosed TBM patients (p \ 0.01).
Conclusions Detection of ESAT-6 in the CSF of TBM
patients by indirect ELISA protocol gives a reliable early
diagnosis and can be used to develop an immunodiagnostic
assay with increased sensitivity and specificity.
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Introduction
Tuberculosis (TB) remains a major public health problem
in the twenty-first century. A third of the world’s popula-
tion is infected with Mycobacterium tuberculosis (MTB);
among them, 5–10 % of the infected population will
develop the disease during their lifetime, and TBM affects
about 7–12 % [1] of all tuberculosis patients. However,
about 30 % of patients with TBM will die despite anti-
tuberculosis chemotherapy [2]. TB is responsible for [2
million deaths per year worldwide. The situation is exac-
erbated by co-infection with human immunodeficiency
virus (HIV).
The diagnosis of TBM relies on the isolation of MTB
from CSF, but direct staining of CSF for acid-fast bacilli
has very low sensitivity (10–20 %) [3]; bacilli cultures
usually take 4–6 weeks and also lack sensitivity (25–70 %)
[4, 5]. Yet, timely diagnosis and treatment will have a
direct influence on the prognosis. So, new, affordable,
sensitive, specific diagnostic assays are required.
In the present study, we used the method of indirect
ELISA to detect the mycobacterial antigen ESAT-6.
ESAT-6 is an early secreted and low molecular weight
protein of MTB, and exists mainly in pathogenic myco-
bacteria but not in all M. bovis BCG strains or in most
environmental mycobacterials examined so far [6]. Previ-
ous studies on ESAT-6 concentrated mainly on specific T
cell responses and gamma interferon (IFN-c) induced by
ESAT-6. To our knowledge, there are no reports on the
quantitative detection of ESAT-6 in the CSF of TBM
patients.
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We selected 100 patients from an inpatient department (73
males, 27 females, within the ages of 13–68 years); 10 had
confirmed TBM (the direct staining of the CSF for acid-fast
bacilli and/or cultures for bacilli were positive), 40 were
diagnosed by clinical symptoms based on the criterion of
Thwaites [5]. All cases above were diagnosed in\2 weeks
after the onset of their disease, and the cases were more
severe in the confirmed TBM group; four with active
pulmonary tuberculous, four with tuberculoma, and two
with spinal cord involvement. Non-TBM diseases (n = 50)
were selected for the control, including multiple sclerosis
(n = 10), acute myelitis (n = 10), viral meningitis
(n = 10), purulent meningitis (n = 8), cryptococcal men-
ingitis (n = 2), and healthy controls (n = 10). Samples
were collected from all study groups for which patient’s
consent and the ethical committee’s approval was obtained.
Antigen and antibody
The recombinant pure antigen ESAT-6 (standard product)
was bought from ProSpec (USA). The primary mAb
against ESAT-6 and the secondary mAb (peroxidase con-
jugate goat anti-mouse IgG) were bought from Abcam
(UK).
Specimens
CSF was obtained from the 100 patients by puncture as
soon as they were diagnosed and stored at -80 C until it
use.
Establishing a standard curve
Prior to patient sampling, the assay was standardized by
incubating purified ESAT-6 with the mAb against ESAT-6
at different dilutions, using the indirect ELISA method (see
the method in following text) to detect the absorbance of
the standard product at different dilutions and to establish a
standard curve, with concentration on the X axis vs.
absorbance on the Y axis (Fig. 1). The different dilutions of
the standard product were prepared by diluted in coating
buffer (3.03 g Na2CO3, 6.0 g NaHCO3, 1,000 ml distilled
water, pH 9.6) at 1, 2, 5, 10, 25, 50, 100, and 200 ng/ml.
Indirect ELISA protocol
CSF samples in a volume of 50 ll (the same as the stan-
dard product) from TBM patients and control subjects were
added to each well, and incubated for 2 h at room
temperature. Then, the plate was washed twice by filling
the wells with 20 ll of phosphate-buffered saline (PBS).
The remaining protein-binding sites in the wells were
blocked by adding 200 ll of 5 % non-fat dry milk per well,
then incubated overnight at 4 C and washed five times
with 200 ll of PBS. The primary mAb (1:3,200, diluted in
5 % non-fat dry milk) was added (100 ll) in each well and
incubated for 2 h at room temperature in the dark. The
wells were then washed five times with 200 ll of PBS. The
secondary antibody (1:5,000, diluted in 5 % non-fat dry
milk; 100 ll) was added to each well and incubated for 2 h
at room temperature in the dark. Then, the plate was
washed five times with 200 ll of PBS; 100 ll the SUBS-
TBM substrate was added to the wells and incubated at
room temperature for 15 min, also in the dark. The reaction
was then stopped with 100 ll of 0.3 M H2SO4 (stopping
buffer) after sufficient color development. The absorbance
of each well was read at 450 nm. Then, we calculated the
concentration of each sample from the standard curve.
Statistical analysis
Results are reported as mean ± standard deviation; dif-
ferences between the TBM patient groups and controls and
between the confirmed TBM group and the clinically
diagnosed group were analyzed by t tests using SPSS
software (version 13; SPSS Inc, Chicago, IL, USA). The
adopted level of statistical significance was p \ 0.05.
Results
The minimum antigen level that could be detected was
1 ng/ml, so patients with a level of ESAT-6 in the CSF
greater than 1 ng/ml were considered positive cases. The
proportions of CSF cases positive for ESAT-6 in the con-
firmed and clinically diagnosed TBM patients were 90 %
Fig. 1 The standard curve of ESAT-6 antigen in CSF by the ELISA
protocol developed in this study
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(9/10) and 87.5 % (35/40), respectively, while the positive
rate for patients in the control group was 8 % (4/50).
Overall, the indirect ELISA method provided 88 % sensi-
tivity and 92 % specificity for the diagnosis of TBM using
a mAb to ESAT-6. The mean concentration of ESAT-6 in
the CSF of TBM patients was 85.13 ± 18.18 ng/ml, which
was significantly higher than that of the non-TBM groups
(2.76 ± 1.57 ng/ml, p \ 0.001). There was also a signifi-
cant difference in the mean ESAT-6 expression between
the confirmed TBM patients (112.87 ± 16.67 ng/ml) and
the clinically diagnosed TBM patients (78.20 ± 10.22 ng/
ml, p \ 0.001). In the TBM patient group, the level of
ESAT-6 in the CSF was [70 ng/ml in 24 cases, and 14 of
them had neurological sequelae, such as headache, epi-
lepsy, or limb weakness. Patients with an ESAT-6 level
below 70 ng/ml had no neurological sequelae (Table 1).
Discussion
Early diagnosis of TBM is still difficult; besides conven-
tional experimental methods, immunoassays have been
recently adopted. Various immunoassays for detecting
antigens or antibodies in the serum or CSF of TBM patients
have been developed with different sensitivities and spec-
ificities. A purified protein derivative (PPD) from MTB, i.e.
a complex mixture of antigens, has long been used as a skin
test for TB diagnosis. The tuberculin skin test (TST) is
technically simple, but it lacks diagnostic specificity in
BCG-vaccinated individuals. Another widely used diag-
nostic test is polymerase chain reaction (PCR) using spe-
cific primers as markers for MTB, but this test is not
performed correctly in all clinical laboratories and shows
variable sensitivity and specificity. Many serological
assays have been tried, but nearly all have failed to
improve upon the time-honored sputum smear and culture
approach. Currently, it is believed that antigen detection is
more sensitive than antibody detection [7], especially
specific MTB antigens such as ESAT-6 and the Ag85
complex. However, the early phase of MTB infection, in
patients treated with corticosteroids, or in immune-defi-
cient TBM patients, these tests may provide false negative
results when antibody detection is used, and antibody
detection cannot distinguish whether it is an acute infection
or a latent infection. Therefore, there has been growing
interest in antigen detection to diagnose TBM [8].
Since the identification of MTB ESAT-6, there has been
growing interest in the use of this antigen to diagnose TB.
In previous studies, it was demonstrated that most TB
patients (35–92 %) can recognize ESAT-6, while healthy
unrelated controls do not [8–12]. ESAT-6 is an immuno-
dominant T cell stimulatory antigen and is recognized by
specific IFN-c-secreting T cells present in greater numbers
in patients who have an active infection compared with
those who are uninfected with MTB [13]. Moreover, the
numbers of specific IFN-c-secreting T cells are signifi-
cantly higher in the CSF than in the peripheral blood [14,
15]. ESAT-6-induced specific IFN-c responses have been
shown to be useful in discriminating infected individuals
from healthy controls [16–18]. Consequently, the possible
use of ESAT-6 as a marker of Mycobacterium tuberculosis
infection has been proposed in regions with low TB
endemicity [19].
Murakami [15] reported a case that was diagnosed with
TBM based on the detection of ESAT-6-specific IFN-c
production in CSF by ELISPOT (an enzyme-linked im-
munospot assay). Mathai [20] reported that detecting PPD
antigen in CSF by Dot-Iba (a dot-immunobinding assay)
provided a sensitivity of 83.3 % and specificity of 95 %.
Similarly, Kashyap [21] also detected ESAT-6 by an
indirect ELISA protocol; the sensitivity was 80 % and the
specificity was 86 %. Overall, these findings support our
results, suggesting that the detection of ESAT-6 in CSF
might be developed into a diagnostic test for TBM.
In the present study, using an indirect ELISA method,
we conducted a prospective study to demonstrate ESAT-6
in the CSF of TBM patients using a mAb against the
antigen. The data demonstrate that positivity for ESAT-6 in
cases of confirmed and clinically diagnosed TBM patients
was 90 % (9/10) and 87.5 % (35/40), respectively, while
the positivity for patients in the non-TBM group was 8 %
(4/50), the sensitivity of detecting ESAT-6 in CSF for
diagnosing TBM was 88 % and the specificity was 92 %.
The minimum antigen level that could be detected was
1 ng/ml, suggesting that the indirect ELISA method is
quite sensitive. However, in the non-TBM group, four
cases were positive. The reason for these false-positive
results is not clear, as test error cannot be ruled out, but
these levels of ESAT-6 were much lower than those in
TBM patients (p \ 0.001). Another finding is that, in the
confirmed TBM group, the level of ESAT-6 was higher
than in the clinically diagnosed group (p \ 0.001). This
could be that confirmed, diagnosed TBM patients showed
more severe clinical manifestations; so it can be speculated
that the level of ESAT-6 in CSF is higher in more severe
patients. In the TBM patient group, 14 cases with a level of
ESAT-6 in the CSF [70 ng/ml had neurological sequelae,
Table 1 The mean concentration of ESAT-6 in CSF in each group
Group n Concentration (ng/ml)
Confirmed TBM patients 10 112.87 ± 16.67
Clinically diagnosed TBM patients 40 78.20 ± 10.22
Control 50 2.76 ± 1.57
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but patients with a level of ESAT-6 \70 ng/ml had no
neurological sequelae. Accordingly, the level of ESAT-6 in
CSF can differentiate between severe infection and mild
infection in TMB and could help clinicians estimate the
prognosis of the disease. On the other hand, all the TBM
cases in the present study were diagnosed \2 weeks after
the onset of disease, and the indirect ELISA test can be
completed in 24 h. Therefore, the present assay is appro-
priate for early diagnosis of TBM with high sensitivity and
specificity.
In this study, detection of ESAT-6 in TBM patients by
indirect ELISA gave a reliable early diagnosis of TBM,
and the test is rapid, sensitive, cost-effective, and could be
performed in any standard pathology laboratory. It could be
used for developing an immunodiagnostic assay with
increased sensitivity and specificity.
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